Personalized mRNA Cancer Vaccine Cuts Melanoma Recurrence or Death Risk by 42%, Trial Reports
Australian-led research has reported a major advance in cancer treatment, with a personalized mRNA vaccine significantly reducing the risk of melanoma recurrence or death. The experimental vaccine, administered after surgery, is the first therapeutic mRNA cancer vaccine reported to achieve positive results in a large phase 3 trial.
Developed by Moderna and Merck, the vaccine was tested alongside the established immunotherapy pembrolizumab, marketed as Keytruda. Among patients with high-risk melanoma, the combination reduced the risk of recurrence or death by 42% compared with pembrolizumab alone.
How the personalized vaccine works
To create the individualized vaccine, doctors first sequence each patient's tumor to identify mutations that distinguish cancer cells from healthy tissue. These mutations form a unique molecular fingerprint, known as a neoantigen profile, specific to the patient's melanoma.
Scientists then develop an mRNA vaccine encoding dozens of these tumor-specific targets. Once administered, the mRNA instructs the patient's cells to produce and display fragments of these targets, helping train the immune system to recognize and attack any remaining melanoma cells.
Keytruda, a checkpoint inhibitor, works by restoring the activity of immune cells that cancer can otherwise suppress. While Keytruda is administered as a standard treatment, the mRNA vaccine is individually designed, making the combination a highly personalized cancer treatment strategy.
Details from the phase 3 trial
The phase 3 INTerpath-001 trial enrolled more than 1,100 patients across 157 sites worldwide. All participants had undergone surgery to remove advanced melanoma but remained at high risk of recurrence. They were randomly assigned to receive either pembrolizumab alone or pembrolizumab combined with the personalized mRNA vaccine.
Researchers reported that the combination reduced the overall risk of melanoma recurrence or death by 42%. Among patients who remained cancer-free six months after starting treatment, the reduction reached 58% compared with immunotherapy alone.
The findings, presented at the European Society for Medical Oncology Congress 2026, confirmed and extended promising phase 2 results published in 2024. Full peer-reviewed findings are expected in The New England Journal of Medicine following regulatory and editorial review.
Why melanoma is a key target
Melanoma is among the most aggressive forms of skin cancer and remains a major public health concern in countries with high sun exposure, including Australia. Approximately one person dies from melanoma every six hours in Australia, despite improvements in screening and treatment.
Existing treatments, including surgery and immunotherapy, have improved survival outcomes, but many high-risk patients still experience recurrence. A vaccine that substantially reduces this risk could improve long-term outcomes and potentially decrease the need for additional treatments with significant side effects.
Researchers consider melanoma a particularly suitable target for mRNA cancer vaccines because these tumors often contain numerous mutations, producing neoantigens that the immune system can recognize. Success in melanoma could therefore support the development of similar approaches for other difficult-to-treat cancers.
Implications for future cancer care
Oncologists view the trial as important evidence supporting the potential of personalized neoantigen vaccines. If approved by regulators, the treatment could become part of standard postoperative care for patients with high-risk melanoma, particularly alongside established immunotherapies.
Researchers are also investigating similar mRNA vaccines for lung, colorectal, and head and neck cancers. However, some early randomized studies involving these cancers have not demonstrated reduced recurrence, suggesting that effectiveness may depend on tumor biology and vaccine design.
Despite these mixed findings, the melanoma results indicate that personalized vaccines may strengthen immune responses against certain cancers. Scientists hope improvements in neoantigen selection and treatment combinations will increase their effectiveness against other tumor types.
Regulatory path and remaining questions
The personalized mRNA melanoma vaccine is not yet available outside clinical trials in Australia, the United States, or Europe. Moderna and Merck have begun regulatory submissions, although approval processes could take years as authorities evaluate safety, long-term effectiveness, and cost.
Important questions remain about how long protection lasts, whether booster doses will be necessary, and whether healthcare systems can make individualized treatments widely accessible. Producing a separate vaccine for each patient also presents considerable manufacturing and financial challenges.
Nevertheless, specialists consider the findings a significant development in immuno-oncology. Personalized vaccines combined with checkpoint inhibitors could eventually become an important strategy for preventing cancer recurrence rather than treating disease only after it spreads.
Australia's experience with HPV vaccination, which has substantially reduced cervical cancer rates, illustrates the potential of immune-based prevention. Although the melanoma vaccine aims to prevent recurrence rather than initial cancer development, both approaches reflect growing interest in using the immune system to improve cancer outcomes.
As additional trial results become available, researchers and regulators will better determine when and how personalized mRNA cancer vaccines should be used. For now, the phase 3 melanoma findings offer encouraging evidence that individualized immunotherapy may help more patients remain cancer-free for longer.
